Petros Pharmaceuticals annual depreciation and amortization
2020
2021
2022
2023
2024
Petros Pharmaceuticals Depreciation & Amortization Growth & History (PTPI)
Petros Pharmaceuticals's depreciation and amortization was $2.8M for fiscal 2024.
View full Petros Pharmaceuticals company overviewPetros Pharmaceuticals annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2024 | 2024-12-31 | $2.8M | −$451,748 | −13.76% |
| 2023 | 2023-12-31 | $3.3M | −$2.3M | −41.36% |
| 2022 | 2022-12-31 | $5.6M | −$1.3M | −18.60% |
| 2021 | 2021-12-31 | $6.9M | $217,552 | +3.27% |
| 2020 | 2020-12-31 | $6.7M | — | — |
Petros Pharmaceuticals quarterly depreciation and amortization
Q1.20
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q4.24
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q4 2024 | 2024-12-31 | $667,294 | — | — |
| Q3 2024 | 2024-09-30 | $739,449 | −$87,346 | −10.56% |
| Q2 2024 | 2024-06-30 | $717,838 | −$108,957 | −13.18% |
| Q1 2024 | 2024-03-31 | $717,839 | −$108,956 | −13.18% |
| Q3 2023 | 2023-09-30 | $826,795 | −$734,075 | −47.03% |
| Q2 2023 | 2023-06-30 | $826,795 | −$734,075 | −47.03% |
| Q1 2023 | 2023-03-31 | $826,795 | −$734,075 | −47.03% |
| Q3 2022 | 2022-09-30 | $1.6M | −$167,959 | −9.72% |
| Q2 2022 | 2022-06-30 | $1.6M | −$167,958 | −9.72% |
| Q1 2022 | 2022-03-31 | $1.6M | −$167,959 | −9.72% |
| Q3 2021 | 2021-09-30 | $1.7M | $67,467 | +4.06% |
| Q2 2021 | 2021-06-30 | $1.7M | $67,468 | +4.06% |
| Q1 2021 | 2021-03-31 | $1.7M | $67,467 | +4.06% |
| Q3 2020 | 2020-09-30 | $1.7M | — | — |
| Q2 2020 | 2020-06-30 | $1.7M | — | — |
| Q1 2020 | 2020-03-31 | $1.7M | — | — |
Petros Pharmaceuticals depreciation and amortization trends
Between the periods ended 2020-12-31 and 2024-12-31, Petros Pharmaceuticals's depreciation and amortization decreased from $6.7M to $2.8M, a change of −$3.8M. The latest reported quarter, Q4 2024, shows $667,294.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Petros Pharmaceuticals source filings ↗